$10.37
1.47% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
NL0015285941
Symbol
IMTX

Immatics N.V Stock price

$10.37
-0.23 2.17% 1M
+4.93 90.63% 6M
+3.26 45.85% YTD
+3.27 46.06% 1Y
+1.86 21.86% 3Y
+0.38 3.80% 5Y
+0.77 8.02% 10Y
+0.77 8.02% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.15 1.47%
ISIN
NL0015285941
Symbol
IMTX
Industry

New AI Insights on Immatics N.V Insights AI Insights on Immatics N.V

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$902.2m
Net debt
positive
Cash
$507.3m
Shares outstanding
121.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.9 | 30.6
EV/Sales
9.0 | 19.9
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
82.6%
Return on Equity
2.7%
ROCE
-31.2%
ROIC
-272.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$99.8m | $45.4m
EBITDA
$-153.0m | $-216.8m
EBIT
$-167.5m | $-228.6m
Net Income
$-136.5m | $-238.3m
Free Cash Flow
$-216.6m
Growth (TTM | estimate)
Revenue
-26.6% | -75.3%
EBITDA
-130.8% | -517.8%
EBIT
-111.5% | -402.7%
Net Income
-107.7% | -1,430.0%
Free Cash Flow
-313.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-153.3% | -477.4%
EBIT
-167.8%
Net
-136.7% | -524.7%
Free Cash Flow
-217.0%
More
EPS
$-1.1
FCF per Share
$-1.8
Short interest
5.7%
Employees
646
Rev per Employee
$280.0k
Show more

Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Immatics N.V Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Immatics N.V forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Immatics N.V forecast:

Buy
94%
Hold
6%

Financial data from Immatics N.V

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
100 100
27% 27%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 60 60
18% 18%
60%
- Research and Development Expense 207 207
26% 26%
208%
-153 -153
131% 131%
-153%
- Depreciation and Amortization 14 14
12% 12%
15%
EBIT (Operating Income) EBIT -167 -167
112% 112%
-168%
Net Profit -136 -136
108% 108%
-137%

In millions USD.

Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immatics N.V Stock News

Positive
Seeking Alpha
about 16 hours ago
Immatics executes a three-wave strategy, progressing from melanoma treatment to broader solid tumors and scalable bispecific TCR therapeutics. IMTX's $505.8M cash position funds operations through 2027, covering BLA submission and anticipated commercial launch, reducing near-term financing risk. Anzu-cel's Phase 3 SUPRAME trial and IMA203CD8's promising ovarian cancer data support a robust, exp...
Neutral
GlobeNewsWire
14 days ago
Houston , Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors. Based on the enha...
Neutral
GlobeNewsWire
20 days ago
Houston, Texas and Tuebingen, Germany,  December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the un...
More Immatics N.V News

Company Profile

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Head office Netherlands
CEO Harpreet Singh-Jasuja
Employees 646
Founded 2020
Website immatics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today